RE: SPACs back from brink with NK cell therapy biotech's plans for blank-check merger29 Mar 2023 09:52
Fruits - hedges cost vast amounts of money. Polygon are, by their own admission, high conviction investors. I don’t think you can say for certainty they have a hedge in place that will potentially muddy the returns.
My point is that they cannot sell. In fact, I’d say it’s impossible for them to sell 60m shares on the open market now.
With regards to being shafted, there are countless examples of where there has been a great company that has gone on to make stacks of cash but the PI’s who supported them 99% of the way got screwed over.
Some of us might have dabbled with likes of SXX to understand
… *shiver*
Anyway, still hopeful. But it is a concern of mine.